Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
162 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mylan Investigational Site
Red Deer, Alberta, Canada
- Mylan Investigational Site
Vancouver, British Columbia, Canada
- Mylan Investigational Site
Winnipeg, Manitoba, Canada
- Mylan Investigational Site
Laval, Quebec, Canada
- Mylan Investigational Site
Mirabel, Quebec, Canada
- Mylan Investigational Site
Montreal, Quebec, Canada
- Mylan Investigational Site
Brno, Czechia
- Mylan Investigational Site
Brno, Czechia
- Mylan Investigational Site
Broumov, Czechia
- Mylan Investigational Site
Bruntál, Czechia
- Mylan Investigational Site
Olomouc, Czechia
- Mylan Investigational Site
Pardubice, Czechia
- Mylan Investigational Site
Prague, Czechia
- Mylan Investigational Site
Prague, Czechia
- Mylan Investigational Site
České Budějovice, Czechia
- Mylan Investigational Site
Pärnu, Estonia
- Mylan Investigational Site
Tallinn, Estonia
- Mylan Investigational Site
Tartu, Estonia
- Mylan Investigational Site
Hohenmölsen, Anhalt, Germany
- Mylan Investigational Site
Wangen, Baden-Wurttemberg, Germany
- Mylan Investigational Site
Aschaffenburg, Bavaria, Germany
- Mylan Investigational Site
Schweinfurt, Bavaria, Germany
- Mylan Investigational Site
Frankfurt am Main, Hesse, Germany
- Mylan Investigational Site
Münster, North Rhine-Westphalia, Germany
- Mylan Investigational Site
Sankt Ingbert, Saarland, Germany
- Mylan Investigational Site
Dresden, Saxony, Germany
- Mylan Investigational Site
Hamburg, Germany
- Mylan Investigational Site
Hamburg, Germany
- Mylan Investigational Site
Baja, Hungary
- Mylan Investigational Site
Budapest, Hungary
- Mylan Investigational Site
Budapest, Hungary
- Mylan Investigational Site
Budapest, Hungary
- Mylan Investigational Site
Eger, Hungary
- Mylan Investigational Site
Gyula, Hungary
- Mylan Investigational Site
Létavértes, Hungary
- Mylan Investigational Site
Makó, Hungary
- Mylan Investigational Site
Miskolc, Hungary
- Mylan Investigational Site
Szeged, Hungary
- Mylan Investigational Site
Kuldīga, Latvia
- Mylan Investigational Site
Limbaži, Latvia
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2014
- Primary completion
- 31 Jul 2016
- Completion
- 31 Jul 2016
- Last update posted
- 3 Mar 2022
- Registered enrollment
- 558
- Registry id
- NCT02227862
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.